丙戊酸钠相关性高氨血症脑病

燚辉 侯

摘要


丙戊酸钠是一种常见的抗癫痫药物，常用于控制癫痫发作、偏头痛和精神疾病等。通常不良反应轻微，然而应用丙戊酸钠后可出现一种罕见、严重的并发症，即丙戊酸钠相关性高氨血症脑病。当患者应用丙戊酸钠出现急性、慢性脑病症状时，应高度怀疑该病，最有效的治疗是及时停药、降氨和补充左旋肉碱。论文就丙戊酸钠脑病的危险因素、发病机制、临床表现、诊断和治疗的最新研究进展进行综述，以期为临床诊治丙戊酸钠相关性高氨血症脑病提供借鉴。

关键词


丙戊酸钠；高氨血症；脑病

全文:

PDF

参考


Wu J, Li J, Jing W, et al. Valproic acid-induced encephalopathy: A review of clinical features, risk factors, diagnosis, and treatment[J]. Epilepsy Behav, 2021(120): 107967.

Woo PYM, Woo AWY, Lam SW, et al. Incidence, Presentation, and Risk Factors for Sodium Valproate-Associated Hyperammonemia in Neurosurgical Patients: A Prospective, Observational Study[J]. World Neurosurg, 2020(144): e597-e604.

Baumgartner J, Hoeflich A, Hinterbuchinger B, et al. Fulminant Onset of Valproate-Associated Hyperammonemic Encephalopathy[J]. Am J Psychiatry, 2019,176(11): 900-903.

Duman B, Can KC, Ağtaş-Ertan E, et al. Risk factors for valproic acid induced hyperammonemia and its association with cognitive functions[J]. Gen Hosp Psychiatry, 2019(59): 67-72.

朱丹化,苏志鹏,叶盛,等.丙戊酸钠脑病的临床误诊分析[J].中华 医学杂志,2014,94(33):2610-2612.

王晓斌,张宇,敬华军,等.丙戊酸钠相关的高血氨脑病[J].中国神 经精神疾病杂志,2013,39(2):123-126.

Chicharro AV, de Marinis AJ, Kanner AM. The measurement of ammonia blood levels in patients taking valproic acid: looking for problems where they do not exist?[J]. Epilepsy Behav, 2007,11(3):361-366.

Yagi M, Nakamura T, Okizuka Y, et al. Effect of CPS14217C>A genotype on valproic-acid-induced hyperammonemia[J]. Pediatr Int :Official Journal of the Japan Pediatric Society, 2010,52(5): 744-748. [9] Noh Y, Kim DW, Chu K, et al. Topiramate increases the risk of valproic acid-induced encephalopathy[J]. Epilepsia, 2013,54(1): e1-e4.

Lewis C, Tesar GE, Dale R. Valproate-Induced Hyperammonemic Encephalopathy in General Hospital Patients With One or More Psychiatric Disorders[J]. Psychosomatics, 2017,58(4): 415-420.

De Michele G, Sorrentino P, Nesti C, et al. Reversible Valproate- Induced Subacute Encephalopathy Associated With a MT-ATP8 Variant in the Mitochondrial Genome[J]. Front Neurol, 2018(9): 728. [12] Zhu X, Li X, Zhang T, et al. Risk Factors for Valproic Acid- induced Hyperammonaemia in Chinese Paediatric Patients with Epilepsy[J]. Basic Clin Pharmacol Toxicol, 2018, 123(5): 628-634. [13] May T, Rambeck B. Serum concentrations of valproic acid: influence of dose and comedication[J]. Ther Drug Monit, 1985,7(4): 387-390.

Chopra A, Kolla BP, Mansukhani MP, et al. Valproate-induced hyperammonemic encephalopathy: an update on risk factors, clinical correlates and management[J]. Gen Hosp Psychiatry, 2012,34(3): 290-298.

Rodrigues-Silva N, Venâncio Â, Bouça J. Risperidone, a risk factor for valproate-induced encephalopathy?[J]. Gen Hosp Psychiatry, 2013,35(4): e455-452+e456.

Stergachis AB, Mogensen KM, Khoury CC, et al. A retrospective study of adult patients with noncirrhotic hyperammonemia[J]. J Inherit Metab Dis, 2020,43(6): 1165-1172.

Walker V. Ammonia metabolism and hyperammonemic disorders[J]. Adv Clin Chem, 2014(67).

Kumar A, Suri A, Sharma BS. Severe valproate induced hyperammonemic encephalopathy successfully managed with peritoneal dialysis[J]. Indian J Crit Care Med, 2014,18(7):461-463.

曾健生.高氨血症相关遗传代谢病危重症[J].中国实用儿科杂 志,2015,30(8):573-578.

Camilleri L. Lesson of the month 1: Sodium valproate-induced encephalopathy[J]. Clin Med (Lond), 2018,18(5):430-432.

朱占胜,李茂坤.丙戊酸钠诱发高氨血症脑病研究进展[J].脑与 神经疾病杂志,2013,21(5):389-391.

孙振晓,于相芬.丙戊酸钠导致高氨血症及脑病的研究进展[J]. 中华临床医师杂志(电子版),2012,6(8):2163-2164.

Vakrinou A, Murphy E, Sisodiya SM, et al. Risk factors and outcome of hyperammonaemia in people with epilepsy[J]. J Neurol, 2022,269(12):6395-6405.

Maldonado C, Guevara N, Silveira A, et al. L-Carnitine supplementation to reverse hyperammonemia in a patient undergoing chronic valproic acid treatment: A case report[J]. J Int Med Res, 2017, 45(3): 1268-1272.

陈晶贞,朱仁敬,林晓芳,等.丙戊酸致高氨血症脑病二例并文献 复习[J].实用药物与临床,2019,22(7):730-733.

Cherian KA, Legatt AD. Burst Suppression Pattern on Electroencephalogram Secondary to Valproic Acid-Induced Hyperammonemic Encephalopathy[J]. Pediatr Neurol, 2017,73: 88-91.

马璐,郑彬,宋立芳.儿童丙戊酸钠相关性高血氨脑病的影像及临 床表现[J].实用医学影像杂志,2020,21(6):573-575.

Ziyeh S, Thiel T, Spreer J, et al. Valproate-induced encephalopathy: assessment with MR imaging and 1H MR spectroscopy[J]. Epilepsia, 2002, 43(9): 1101-1105.

Farooq F, Sahib Din J, Khan AM, et al. Valproate-Induced Hyperammonemic Encephalopathy[J]. Cureus, 2017, 9(8): e1593. [30] Ghannoum M, Laliberté M, Nolin TD, et al. Extracorporeal treatment for valproic acid poisoning: systematic review and recommendations from the EXTRIP workgroup[J]. Clin Toxicol (Phila), 2015, 53(5): 454-465.

Meijer R, Vivekananda U, Balestrini S, et al. Ammonia: what adult neurologists need to know[J]. Pract Neurol, 2020.

Maldonado C, Guevara N, Silveira A, et al. L-Carnitine supplementation to reverse hyperammonemia in a patient undergoing chronic valproic acid treatment: A case report[J]. J Int Med Res, 2017, 45(3): 1268-1272.

Schrettl V, Felgenhauer N, Rabe C, et al. L-Arginine in the treatment of valproate overdose - five clinical cases[J]. Clin Toxicol (Phila), 2017, 55(4): 260-266.




DOI: https://doi.org/10.12346/pmr.v5i4.8981

Refbacks

  • 当前没有refback。